Research programme: aspirin/protein pump inhibitors - Aralez Pharmaceuticals

Drug Profile

Research programme: aspirin/protein pump inhibitors - Aralez Pharmaceuticals

Latest Information Update: 22 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator POZEN
  • Developer Aralez Pharmaceuticals Inc.
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Non-opioid analgesics; Salicylic acids; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Cardiovascular disorders; NSAID-induced ulcer

Most Recent Events

  • 01 Oct 2012 Research programme: aspirin/protein pump inhibitors - POZEN is available for partnering as of 01 Oct 2012.
  • 03 Aug 2012 PA 10040 is still in preclinical trials for Cardiovascular disorders (prevention) in USA
  • 12 Apr 2012 POZEN is assessing the regulatory and development requirements for a possible indication in the secondary prevention of colorectal neoplasia. The company received input from the US FDA on this in January 2010 (POZEN Form 10-K filed 9 Mar 2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top